CD89 Is a Potent Innate Receptor for Bacteria and Mediates Host Protection from Sepsis.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
16 04 2019
Historique:
received: 29 05 2018
revised: 11 01 2019
accepted: 15 03 2019
entrez: 18 4 2019
pubmed: 18 4 2019
medline: 17 6 2020
Statut: ppublish

Résumé

Direct bacterial recognition by innate receptors is crucial for bacterial clearance. Here, we show that the IgA receptor CD89 is a major innate receptor that directly binds bacteria independently of its cognate ligands IgA and c-reactive protein (CRP). This binding is only partially inhibited by serum IgA and induces bacterial phagocytosis by CD11c

Identifiants

pubmed: 30995475
pii: S2211-1247(19)30392-4
doi: 10.1016/j.celrep.2019.03.062
pii:
doi:

Substances chimiques

Antigens, CD 0
Cytokines 0
Fc(alpha) receptor 0
Immunoglobulin A 0
Receptors, Fc 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

762-775.e5

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Christian de Tymowski (C)

INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; CNRS ERL8252, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Site Xavier Bichat, Paris, France; Inflamex Laboratory of Excellence, Paris, France.

Nicholas Heming (N)

INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; CNRS ERL8252, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Site Xavier Bichat, Paris, France; Inflamex Laboratory of Excellence, Paris, France.

Mario D T Correia (MDT)

Emergency Medicine Department, Medical School, University of São Paulo, São Paulo, Brazil.

Lilia Abbad (L)

INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; CNRS ERL8252, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Site Xavier Bichat, Paris, France; Inflamex Laboratory of Excellence, Paris, France.

Nathalie Chavarot (N)

INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; CNRS ERL8252, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Site Xavier Bichat, Paris, France; Inflamex Laboratory of Excellence, Paris, France.

Marie-Bénédicte Le Stang (MB)

INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; CNRS ERL8252, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Site Xavier Bichat, Paris, France; Inflamex Laboratory of Excellence, Paris, France.

Heloise Flament (H)

INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; CNRS ERL8252, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Site Xavier Bichat, Paris, France; Inflamex Laboratory of Excellence, Paris, France.

Julie Bex (J)

INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; CNRS ERL8252, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Site Xavier Bichat, Paris, France; Inflamex Laboratory of Excellence, Paris, France.

Erwan Boedec (E)

INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; CNRS ERL8252, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Site Xavier Bichat, Paris, France; Inflamex Laboratory of Excellence, Paris, France.

Carine Bounaix (C)

INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; CNRS ERL8252, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Site Xavier Bichat, Paris, France; Inflamex Laboratory of Excellence, Paris, France.

Rafael Soler-Torronteras (R)

INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; CNRS ERL8252, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Site Xavier Bichat, Paris, France; Inflamex Laboratory of Excellence, Paris, France.

Erick Denamur (E)

Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Site Xavier Bichat, Paris, France; INSERM U1137, IAME, Paris, France.

Lionel Galicier (L)

Department of Clinical Immunology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), Paris, France; EA3518, Université Paris Diderot Paris 7, Paris, France.

Eric Oksenhendler (E)

Department of Clinical Immunology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), Paris, France; EA3518, Université Paris Diderot Paris 7, Paris, France.

Hans Joerg Fehling (HJ)

Institute of Immunology, University Clinics Ulm, Heidelberg, Germany.

Fabiano Pinheiro da Silva (F)

Emergency Medicine Department, Medical School, University of São Paulo, São Paulo, Brazil.

Marc Benhamou (M)

INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; CNRS ERL8252, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Site Xavier Bichat, Paris, France; Inflamex Laboratory of Excellence, Paris, France.

Renato C Monteiro (RC)

INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; CNRS ERL8252, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Site Xavier Bichat, Paris, France; Inflamex Laboratory of Excellence, Paris, France; Service d'Immunologie, DHU Fire, Assistance Publique de Paris, Hôpital Bichat-Claude Bernard, Paris, France.

Sanae Ben Mkaddem (S)

INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; CNRS ERL8252, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Site Xavier Bichat, Paris, France; Inflamex Laboratory of Excellence, Paris, France. Electronic address: sanae.benmkaddem@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH